Annexon Inc. (ANNX) News
Filter ANNX News Items
ANNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANNX News Highlights
- For ANNX, its 30 day story count is now at 5.
- Over the past 9 days, the trend for ANNX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- DEC, DRUG and PATH are the most mentioned tickers in articles about ANNX.
Latest ANNX News From Around the Web
Below are the latest news stories about ANNEXON INC that investors may wish to consider to help them evaluate ANNX as an investment opportunity.
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. PT in San Francisco. A live webcast of the event can be accessed under th |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockBRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The shares of common stock are being sold at a pr |
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointAlignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled Trial Supporting a Potentially Faster Path to Registration, Expected to Initiate in Mid-2024 ARROW, a Head-to-Head Trial using SYFOVRE® as an Injection Comparator to Differentiate Vision Protection from Slowing of Lesion Growth, Expected to Initiate in Late 2024 BRISBANE, Calif., Dec. 20, 2023 (GLOBE |
Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayTarget Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across Cohorts with No Serious Adverse Events Tablet Formulation of ANX1502 Expected to Advance into Proof-of-Concept Study in Patients with Cold Agglutinin Disease (CAD) in 2024 BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company dev |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on December 13, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4). In th |
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceBRISBANE, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that Douglas Love, president and chief executive officer, will participate in a fireside chat during the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023 at 2:10 p.m. ET in Miami. A live webcast of the event can |
Here's Why Annexon (NASDAQ:ANNX) Must Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Annexon Inc (ANNX) Reports Q3 2023 Financial Results and Clinical ProgressFocus on Priority Programs and Extended Cash Runway |
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial ResultsCompany Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for First Half of 2024 ANX007 Awarded First-Ever PRIME Designation for the Treatment of GA; Global Regulatory Interactions Ongoing to Advance Phase 3 Program ANX1502 Phase 1 Data on Track for Q4 2023 Focused Operations and Resources Support Cash Runway into Q2 20 |